Dr. Berenika Maciejewicz, a triple-doctor and an expert in longevity, leads the company’s interdisciplinary team to ...

The Open University of Kenya has announced 61 job opportunities for academic and administrative staff positions. In a notice ...

The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Healthcare and biotech stocks have had a rough run since the giddy heights of the Covid pandemic. But now could be the perfect time to consider investing in these beaten-down but high-growth sectors.

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

Dec 10 (Reuters) - French biotech company Abivax's (ABVX.PA), opens new tab shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly (LLY.N), opens new tab could make an ...

In the fast-paced world of biotechnology, success hinges on more than groundbreaking science—it requires the right connections, strategic partnerships, and access to capital. Biotech Showcase delivers ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Beverly biotech is working ...

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from government-funded contracts and authorize the Trump administration to bar US ...

If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...

The Trump administration’s ambition to unleash biomedical innovation and sharpen America’s edge against China is colliding with a far messier reality inside the Food and Drug Administration. Investors ...